Yi Li

Li

Yi Li, Ph.D., M.S., B.S.

Professor

(713) 798-3963

Email

liyi@bcm.edu

Positions

Professor
Breast Center; Department of Molecular & Cellular Biology; Department of Molecular Virology & Microbiology
Baylor College of Medicine
Houston, TX, US
Member
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine
Houston, Texas, United States
Faculty Senator
Baylor College of Medicine
Houston, Texas, United States
Member
Dan L Duncan Comprehensive Cancer Center
Baylor College of Medicine

Addresses

BCM-Alkek Graduate School (Lab)
Mail Stop: BCM600
Houston, TX, 77030
United States
Phone: (713) 798-3963
liyi@bcm.edu
BCM-Alkek Graduate School (Office)
Mail Stop: BCM600
Houston, TX, 77030
United States
Phone: (713) 798-3963
liyi@bcm.edu

Education

BS from Jiangsu Agricultural College
07/1984 - Yangzhou, Jiangsu, China, People's Rep
MS from Jiangsu Agricultural College
07/1987 - Yangzhou, Jiangsu, China, People's Rep
PhD from Michigan State University
01/1996 - East Lansing, Michigan, United States
Postdoctoral Training at National Cancer Institute
01/2000 - Bethesda, Maryland, United States
Postdoctoral Training at Memorial Sloan Kettering Cancer Center
10/2002 - New York, New York, United States

Professional Interests

  • Mouse and rat models of breast cancer
  • Immune cells and breast cancer metastasis and therapy
  • JAK-STAT and Bcl-xL signaling breast cancer

Professional Statement

The Li lab has developed multiple novel mouse and rat models that closely mimic human breast cancer initiation and progression. Using these models and cell biological, biochemical, genetic, and omic approaches, they have gained insights into Wnt-EGFR signaling in cancer progression, and discovered a JAK2-STAT5-regulated anti-apoptosis mechanism in promoting breast cancer development. Furthermore, their preclinical work on intermittent anti-JAK treatment for preventing breast cancer has resulted in a multi-center window-of-opportunity clinical trial (TBCRC042). Their recent success in introducing oncogenic drivers directly into mammary cells in rats has led to first models that can fully mimic human ER+ breast cancer. They are now utilizing these models to study how ER+ breast tumors metastasize and develop resistance to cancer therapies.

Selected Publications

Log In to edit your profile